The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1555
Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
The FDA has approved Roxybond (Daiichi Sankyo), an short-acting (SA) oxycodone formulation with abuse-deterrent properties, for treatment of pain requiring management with an opioid. Roxybond is the first SA opioid to be approved as an...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Roxybond - An Abuse-Deterrent Formulation of Short-Acting Oxycodone
Article code: 1555a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.